The psychosocial impact of the COVID-19 pandemic on MGUS, smouldering and active myeloma patients: findings from an international survey.

Early in the COVID-19 pandemic, the UK National Health Service (NHS) identified multiple myeloma (MM) patients as a "clinically extremely vulnerable" population1 . In contrast, the clinical significance of COVID-19 to MM precursors, monoclonal gammopathy of undermined significance (MGUS)2 and smouldering multiple myeloma (SMM)3 , remains unknown. Here for the first time we summarise the impact of the COVID-19 pandemic on 274 MM spectrum individuals (66 MGUS, 33 SMM, 175 MM) who participated in the IMPaCCT (Investigating the impact of COVID-19 on caregivers and patients) study. The first wave of this online international longitudinal study took place between 24 April-14 July 2020.